| SGMO Snapshot | |
|---|---|
| Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic drugs that transform the lives of patients using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company is headquartered in Brisbane, California. | |
| VALUATION DATA | |
| Market Capitalization | $98,799,000 | Price to Sales | 4.00 |
| Earnings per Share | $-1.4800 |
| PE Ratio | None |
| PRICE DATA | |
| Most Recent Close | $0.4851 |
| 52 Week High | $0.628 |
| 52 Week Low | $1.352 |
| 50-Day Moving Average | $0.392 |
| 200-Day Moving Average | $-0.715 |
| All data are from Alpha Vantage as of today. For more infomation on SGMO see Stock Dividend, Valuation, Price and Financial Data for Investors | |
Custom Search